FDA scientists publicly flag evidence gaps in compounded peptides

Ahead of a federal advisory meeting later this month, FDA scientists have publicly said the evidence does not support easing restrictions on a group of compounded peptides that Health Secretary Robert F. Kennedy Jr. has said he wants brought back into wider use ^[1].

On Monday, the FDA posted documents reviewing the science behind seven peptides scheduled for discussion at the Pharmacy Compounding Advisory Committee meeting on July 23 and 24 ^[1]. The list includes BPC-157, TB-500 and MOTs-C, molecules that have become popular online among people seeking help with injuries, muscle recovery, metabolism, and other wellness goals ^[1]. According to the documents, agency scientists concluded there is insufficient evidence to support changing the current designation for any of the seven peptides under review ^[1].

These substances were placed into a restrictive category in 2023 under the Biden administration, a move that effectively barred compounding pharmacies from making them ^[1]. Since then, people who want the peptides have often turned to a gray market, buying products from overseas suppliers with little oversight ^[1]. The July meeting will specifically weigh evidence for uses tied to ulcerative colitis, wound healing, obesity, and migraines ^[1].

Secretary Kennedy has said he wants the FDA to allow compounding pharmacies to offer these peptides again, and has said he has used some of them himself ^[1]. The panel set to make recommendations later this month includes members with ties to the peptide industry, including some who work for companies that sell injectable peptides, according to the FDA's own roster ^[1]. It is not yet known how the panel will weigh its own agency's scientific findings against the political push for wider access ^[1].

Outside experts describe the same evidence gap. Dr. Alexander Weber, an orthopedic surgeon and chief of sports medicine at the University of Southern California who has published a review of the research, said patients ask him about peptides constantly. "My stock answer is that we just don't have enough data to support their use," he said ^[1]. A separate review by ECRI, a nonprofit patient safety organization, reached a similar conclusion about the lack of evidence for these products ^[1].

Why it matters for patients

The outcome of the July meeting could determine whether licensed compounding pharmacies are allowed to legally make these peptides again, changing where and how people access them ^[1]. Right now, people seeking these substances are largely relying on unregulated overseas suppliers, a situation FDA scientists and outside reviewers say carries its own risks because of the gray market's lack of oversight ^[1]. At the same time, the agency's own scientific review found no strong evidence that any of the seven peptides works safely for the specific conditions under discussion, including obesity and migraines ^[1]. That gap between political pressure to expand access and the underlying science means patients weighing these products face genuine uncertainty about both effectiveness and safety, which is not yet resolved by any single study or agency finding ^[1].

What happens next

The Pharmacy Compounding Advisory Committee is scheduled to meet July 23 and 24, 2026, to make recommendations on the seven peptides currently under review, including BPC-157, TB-500 and MOTs-C ^[1]. The panel is expected to reconvene in February 2026 to consider additional peptides not covered in the July session ^[1]. It is not yet known what the committee will recommend or whether the FDA will act on those recommendations ^[1].